MCID: BRN028
MIFTS: 72

Brain Cancer

Categories: Rare diseases, Cancer diseases, Neuronal diseases

Aliases & Classifications for Brain Cancer

MalaCards integrated aliases for Brain Cancer:

Name: Brain Cancer 12 51 14
Adult Brain Tumor 12 51 69
Primary Malignant Neoplasm of Brain 12 69
Malignant Neoplasm of Brain 28 69
Neoplasm of Brain 12 28
Brain Neoplasms 41 69
Brain Tumors 51 40
Neoplasm of Unspecified Nature of Brain 12
Malignant Primary Brain Neoplasm 12
Adult Malignant Brain Neoplasm 12
Malignant Tumor of Adult Brain 12
Malignant Primary Brain Tumors 51
Malignant Primary Brain Tumor 12
Malignant Tumor of Brain 12
Malignant Brain Tumour 12
Primary Brain Neoplasm 12
Brain Neoplasm, Adult 12
Brain Tumor, Primary 69
Primary Brain Tumor 12
Brain Tumor Primary 51
Tumor of the Brain 12
Brain Tumor, Adult 49
Bt - Brain Tumour 12
Brain Neoplasm 12

Classifications:



Summaries for Brain Cancer

MedlinePlus : 40 A brain tumor is a growth of abnormal cells in the tissues of the brain. Brain tumors can be benign, with no cancer cells, or malignant, with cancer cells that grow quickly. Some are primary brain tumors, which start in the brain. Others are metastatic, and they start somewhere else in the body and move to the brain. Brain tumors can cause many symptoms. Some of the most common are Headaches, often in the morning Nausea and vomiting Changes in your ability to talk, hear, or see Problems with balance or walking Problems with thinking or memory Feeling weak or sleepy Changes in your mood or behavior Seizures Doctors diagnose brain tumors by doing a neurologic exam and tests including an MRI, CT scan, and biopsy. Treatment options include watchful waiting, surgery, radiation therapy, chemotherapy, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells. Many people get a combination of treatments. NIH: National Cancer Institute

MalaCards based summary : Brain Cancer, also known as adult brain tumor, is related to atypical teratoid rhabdoid tumor and pilocytic astrocytoma, and has symptoms including sleeplessness, vertigo/dizziness and chronic pain. An important gene associated with Brain Cancer is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are Endometrial cancer and Downstream signaling events of B Cell Receptor (BCR). The drugs Gliadel Wafer and Temodar have been mentioned in the context of this disorder. Affiliated tissues include brain, lung and pituitary, and related phenotypes are Decreased p24 protein expression and homeostasis/metabolism

Disease Ontology : 12 A central nervous system cancer that is characterized by the growth of abnormal cells in the tissues of the brain.

Wikipedia : 72 A brain tumor occurs when abnormal cells form within the brain. There are two main types of tumors:... more...

Related Diseases for Brain Cancer

Diseases related to Brain Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 225)
# Related Disease Score Top Affiliating Genes
1 atypical teratoid rhabdoid tumor 31.4 GFAP SMARCB1 SYP
2 pilocytic astrocytoma 31.2 GFAP IDH1 MGMT PTEN SYP
3 supratentorial cancer 31.0 ENO2 GFAP SMARCB1 SYP TP53
4 brain glioma 30.9 EGFR GFAP MGMT NES TP53
5 hydrocephalus 30.7 ENO2 GFAP NES PTEN SYP TP53
6 hemangioblastoma 30.4 ENO2 GFAP SYP
7 papilloma of choroid plexus 30.3 GFAP SYP TP53
8 anaplastic oligodendroglioma 30.3 EGFR IDH1 MGMT
9 salivary gland cancer 30.0 AKT1 EGFR PTEN
10 infratentorial cancer 30.0 GFAP MYCN NES PTCH1 SMARCB1 SYP
11 glioma 29.8 DMBT1 EGF EGFR IDH1 PTEN TP53
12 thyroid cancer 29.0 AKT1 EGF PTCH1 PTEN TP53
13 glioblastoma 29.0 AKT1 ALK DMBT1 EGF EGFR IDH1
14 oligodendroglioma 29.0 EGFR ENO2 GFAP IDH1 MGMT PTEN
15 malignant glioma 28.9 DMBT1 EGF EGFR GFAP MGMT PTEN
16 glioblastoma multiforme 28.2 AKT1 DMBT1 EGF EGFR GFAP IDH1
17 astrocytoma 27.4 AKT1 DMBT1 EGF EGFR GFAP IDH1
18 medulloblastoma 27.2 AKT1 BMI1 DMBT1 ENO2 GFAP MGMT
19 brain tumor, childhood 12.3
20 prostate cancer/brain cancer susceptibility 11.9
21 childhood germ cell brain tumor 11.9
22 brain stem cancer 11.3
23 erythroplakia 10.7 ABCG2 BMI1
24 large cell carcinoma with rhabdoid phenotype 10.7 ENO2 SMARCB1
25 brain ependymoma 10.6 EGFR TP53
26 mismatch repair cancer syndrome 10.6
27 childhood apraxia of speech 10.6
28 intracranial chondrosarcoma 10.6 IDH1 TP53
29 intracranial cysts 10.6 ENO2 GFAP
30 melanotic medulloblastoma 10.6 ENO2 GFAP SMARCB1
31 cowden syndrome 1 10.6 EGFR PTEN
32 cerebellar astrocytoma 10.5 IDH1 TP53
33 parameningeal embryonal rhabdomyosarcoma 10.5 ALK TP53
34 adenosquamous cell lung carcinoma 10.5 ALK EGFR ENO2
35 soft tissue sarcoma 10.5 ABCB1 EGFR TP53
36 oligoastrocytoma 10.5 GFAP MGMT
37 pharynx cancer 10.5 AKT1 EGFR TP53
38 frontal convexity meningioma 10.5 GFAP TP53
39 gliofibroma 10.5 GFAP TP53
40 malignant sertoli cell tumor 10.5 ENO2 SYP
41 urinary bladder small cell neuroendocrine carcinoma 10.5 ENO2 SYP
42 estrogen-receptor positive breast cancer 10.5 AKT1 EGFR TP53
43 endometrial adenocarcinoma 10.5 EGFR PTEN TP53
44 testicular germ cell tumor 10.5 AKT1 PTEN TP53
45 ductal carcinoma in situ 10.5 AKT1 EGFR TP53
46 anal squamous cell carcinoma 10.5 AKT1 MGMT TP53
47 li-fraumeni syndrome 10.5 EGFR IDH1 PTEN TP53
48 neuroma 10.5 ENO2 GFAP SMARCB1
49 ovarian cancer 1 10.5 AKT1 EGFR PTEN TP53
50 male reproductive organ cancer 10.5 AKT1 PTEN TP53

Comorbidity relations with Brain Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Brain Edema
Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation Hypertension, Essential
Obstructive Hydrocephalus Schizophreniform Disorder

Graphical network of the top 20 diseases related to Brain Cancer:



Diseases related to Brain Cancer

Symptoms & Phenotypes for Brain Cancer

UMLS symptoms related to Brain Cancer:


sleeplessness, vertigo/dizziness, chronic pain, tremor, syncope, seizures, sciatica, pain, headache, back pain

GenomeRNAi Phenotypes related to Brain Cancer according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased p24 protein expression GR00163-A-1 8.92 AKT1 EGF EGFR IDH1

MGI Mouse Phenotypes related to Brain Cancer:

43 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.41 DMBT1 GFAP EGFR BIRC6 AKT1 ABCB1
2 growth/size/body region MP:0005378 10.4 EGFR EGF ENO2 GFAP BIRC6 AKT1
3 behavior/neurological MP:0005386 10.38 ENO2 AKT1 ABCB1 ABCG2 ALK MYCN
4 cellular MP:0005384 10.37 BIRC6 EGFR DMBT1 ENO2 AKT1 ABCG2
5 immune system MP:0005387 10.34 EGFR DMBT1 EGF BIRC6 AKT1 ABCB1
6 mortality/aging MP:0010768 10.32 EGFR DMBT1 BIRC6 AKT1 ABCB1 ALK
7 cardiovascular system MP:0005385 10.3 BIRC6 EGFR AKT1 ABCB1 PTCH1 MYCN
8 hematopoietic system MP:0005397 10.29 BIRC6 EGFR AKT1 ABCB1 ABCG2 PTCH1
9 digestive/alimentary MP:0005381 10.28 DMBT1 EGF GFAP EGFR ABCB1 MYCN
10 endocrine/exocrine gland MP:0005379 10.27 BIRC6 EGFR EGF AKT1 ABCB1 ALK
11 nervous system MP:0003631 10.25 ENO2 GFAP EGFR ABCB1 ALK ABCG2
12 embryo MP:0005380 10.23 BIRC6 EGFR DMBT1 AKT1 PTCH1 MYCN
13 integument MP:0010771 10.16 BIRC6 EGFR EGF AKT1 ABCG2 ALK
14 liver/biliary system MP:0005370 10.15 EGFR BIRC6 AKT1 ABCB1 ABCG2 MYCN
15 normal MP:0002873 10.11 EGF GFAP EGFR ABCG2 BIRC6 AKT1
16 neoplasm MP:0002006 10.09 DMBT1 EGFR ALK AKT1 PTCH1 MGMT
17 muscle MP:0005369 10.06 EGFR AKT1 PTCH1 MYCN GFAP SMARCB1
18 reproductive system MP:0005389 9.85 EGFR EGF AKT1 ABCB1 ALK MYCN
19 renal/urinary system MP:0005367 9.8 DMBT1 EGFR ABCG2 PTCH1 MYCN PTEN
20 pigmentation MP:0001186 9.72 EGFR ALK PTCH1 PTEN TP53
21 respiratory system MP:0005388 9.65 ENO2 EGFR ALK AKT1 IDH1 PTCH1
22 vision/eye MP:0005391 9.28 EGFR EGF ALK MYCN GFAP PTCH1

Drugs & Therapeutics for Brain Cancer

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Gliadel Wafer 17 45 CARMUSTINE Rhone-Poulenc Rorer, Guilford Pharmaceuticals February 1997
2
Temodar 17 45 TEMOZOLOMIDE Schering-Plough August 1999
3
Alecensa 17 ALECTINIB HYDROCHLORIDE Roche December 2015

Drugs for Brain Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 708)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 657311 5754
2
Prednisone Approved, Vet_approved Phase 4,Phase 2 53-03-2 5865
3
Menthol Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 2216-51-5 16666
4
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 1 28523-86-6 5206
5
Dacarbazine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 4342-03-4 5351166
6
Temozolomide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 85622-93-1 5394
7
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3 76631-46-4, 113775-47-6 5311068 56032 68602
8
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
9
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1 2078-54-8 4943
10
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
11
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2 83-43-2 6741
12
Prednisolone Approved, Vet_approved Phase 4,Phase 2 50-24-8 5755
13 Piracetam Approved, Investigational Phase 4,Phase 2 7491-74-9
14
Clevidipine Approved, Investigational Phase 4 167221-71-8
15
Hydralazine Approved Phase 4 86-54-4 3637
16
Labetalol Approved Phase 4 36894-69-6 3869
17
Thrombin Approved, Investigational Phase 4
18
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
19
Methylphenidate Approved, Investigational Phase 4,Phase 3 20748-11-2, 113-45-1 4158
20
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 1 38396-39-3, 2180-92-9 2474
21
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
22
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 437-38-7 3345
23
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
24
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4,Phase 3 7487-88-9 24083
25
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
26
Propranolol Approved, Investigational Phase 4 525-66-6 4946
27
Cabergoline Approved Phase 4,Phase 3,Phase 2 81409-90-7 54746
28
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 83150-76-9 6400441 383414
29
Somatostatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 38916-34-6, 51110-01-1 53481605
30
Remifentanil Approved Phase 4,Phase 3 132875-61-7 60815
31
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
32
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
33
Ibuprofen Approved Phase 4,Phase 3 15687-27-1 3672
34
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2 57-27-2 5288826
35
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
36
Donepezil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 120014-06-4 3152
37
Lamotrigine Approved, Investigational Phase 4,Phase 1,Phase 2 84057-84-1 3878
38
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 2 148553-50-8 5486971
39
Topiramate Approved Phase 4,Phase 1,Phase 2 97240-79-4 5284627
40
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 99-66-1 3121
41
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 1994-09-7, 94-09-7 2337
42
Ephedrine Approved Phase 4 299-42-3 9294
43
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
44
Phenylephrine Approved Phase 4 59-42-7 6041
45
Pseudoephedrine Approved Phase 4 90-82-4 7028
46
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
47
Cefazolin Approved Phase 4 25953-19-9 33255 656510
48
Cefdinir Approved Phase 4 91832-40-5 6915944
49
Cefuroxime Approved Phase 4 55268-75-2 5479529 5361202
50
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029

Interventional clinical trials:

(show top 50) (show all 1892)

# Name Status NCT ID Phase Drugs
1 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
2 Characterization of Receptors in Non-functioning Pituitary Macroadenomas Unknown status NCT00852501 Phase 4
3 Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors Completed NCT02034708 Phase 4 Dotarem®;Gadovist®/Gadavist®
4 Trial of Levetiracetam in Patients With Primary Brain Tumors and Symptomatic Seizures Who Undergo Surgery Completed NCT00571155 Phase 4 levetiracetam
5 Perampanel in Seizure Patients With Primary Glial Brain Tumors Completed NCT02363933 Phase 4 Perampanel
6 Surgery Versus Radiosurgery to Treat Metastatic Brain Tumors Completed NCT00075166 Phase 4
7 A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients Completed NCT00952081 Phase 4 Clevidipine
8 Multihance at 3 Tesla in Brain Tumors Completed NCT00395863 Phase 4 Multihance;Arm 2 - Magnevist
9 Phase IV Bioseal Study in Brain Tumor Surgery Completed NCT02034799 Phase 4
10 Learning Impairments Among Survivors of Childhood Cancer Completed NCT00576472 Phase 4 Methylphenidate
11 Scalp Nerve Block and Opioid Consumption in Brain Surgery Completed NCT02057367 Phase 4 Scalp block with 0.5% plain Marcaine;Scalp block with 0.9% normal saline
12 Sugammadex Given for the Reversal of Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants Completed NCT02708056 Phase 4 Sugammadex
13 The Use of Fentanyl in General Anesthesia for Craniotomy With or Without 0.5% Levobupivacaine Scalp Block Completed NCT02558569 Phase 4 Levobupivacaine
14 Bioequivalence Study of Temozolomide in Patients With Primary Tumors of the Central Nervous System Completed NCT02343081 Phase 4 Temozolomide;Temozolomide
15 Dexmedetomidine and Intelligence Development in Pediatric Patients Undergoing Craniotomy Completed NCT02810899 Phase 4 dexmedetomidine;normal saline
16 Magnesium Sulphate for Attenuation of Hemodynamic Pressor Response After Myfield's Clamp Application Completed NCT03318471 Phase 4 MgSo4;0.9% NaCl
17 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4 itraconazole
18 Crossover Comparison of MultiHance and Dotarem Completed NCT02070380 Phase 4 MultiHance 0.1 mmol/kg;Dotarem;MultiHance 0.05 mmol/kg
19 Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain Completed NCT01613417 Phase 4 gadoteridol;gadobutrol
20 A Study Comparing Two Magnetic Resonance Imaging (MRI) Contrast Agents in MRI of the Brain Completed NCT00323102 Phase 4 Multihance
21 Using Propranolol in Traumatic Brain Injury to Reduce Sympathetic Storm Phenomenon Completed NCT03401515 Phase 4 Propranolol Hydrochloride 1 MG/ML
22 Validation of 3 Dimensional Laparoscopic System in Disral Pancreatectomy and Splenectomy Completed NCT02757690 Phase 4
23 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
24 Remifentanil Infusion Alone During the Closure Period for Early Emergence Following Craniotomy Completed NCT02593942 Phase 4 Remifentanil;Propofol
25 Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors Completed NCT02351700 Phase 4 IV Caldolor (IV Ibuprofen);IV Ibuprofen placebo
26 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
27 Effect of 5 Years of GH Replacement on Atherosclerosis Completed NCT00462475 Phase 4 Recombinant Growth Hormone, Genotropin (Pfizer)
28 Light Sedation or Intubated General Anesthesia in Patients With Brain Cancer Undergoing Craniotomy Recruiting NCT02193568 Phase 4
29 Vasopressor Effects in Anesthetized Patients Recruiting NCT02713087 Phase 4 Ephedrine;Phenylephrine
30 Single Dose Tramadol Effect on Extubation Response and Quality of Emergence Post-supratentorial Intracranial Surgery Recruiting NCT02964416 Phase 4 Injection Tramadol
31 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Recruiting NCT02478346 Phase 4 Fluorescein Sodium
32 Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor Removal by Transphenoid Approach Recruiting NCT03132259 Phase 4 high dose dexmedethomidine;low dose dexmedethomidine
33 Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
34 Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery Recruiting NCT02549768 Phase 4 Dexmedetomidine;Sodium Chloride 0.9%
35 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
36 Quality Improvement and Practice Based Research in Neurology Using the EMR Enrolling by invitation NCT02670161 Phase 4 Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
37 Comparison of Efficacy and Safety of the Postoperative Analgesia Methods Not yet recruiting NCT02929147 Phase 4 Morphine;Dexketoprofen;Placebo
38 Treatment of Resectable Malignant Brain Tumors Terminated NCT00415467 Phase 4
39 Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients Terminated NCT00727090 Phase 4 Conivaptan
40 A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. Terminated NCT01861717 Phase 4 lanreotide
41 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Terminated NCT02028325 Phase 4 Fluorescein Sodium
42 Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Terminated NCT01756729 Phase 4
43 Genetically-informed Therapies for Patients With Metastatic Cancer Withdrawn NCT02000739 Phase 4
44 Efficacy of Tranexamic Acid in Brain Tumor Resections Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
45 Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children Unknown status NCT00749723 Phase 2, Phase 3 carboplatin;etoposide;temozolomide;thiotepa, carboplatin, etoposide;temozolomide, thiotepa;etoposide;trofosfamide/etoposide
46 SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors Unknown status NCT00517959 Phase 3
47 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
48 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
49 Cognitive Rehabilitation of Glioma Patients Unknown status NCT00256425 Phase 3
50 18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology Unknown status NCT00207298 Phase 3

Search NIH Clinical Center for Brain Cancer

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: brain neoplasms

Genetic Tests for Brain Cancer

Genetic tests related to Brain Cancer:

# Genetic test Affiliating Genes
1 Neoplasm of Brain 28
2 Malignant Neoplasm of Brain 28

Anatomical Context for Brain Cancer

MalaCards organs/tissues related to Brain Cancer:

38
Brain, Lung, Pituitary, Breast, T Cells, Testes, Bone

Publications for Brain Cancer

Articles related to Brain Cancer:

(show top 50) (show all 536)
# Title Authors Year
1
Response to 'Perilesional edema in brain cancer: Independent prognosticator or epiphenomenon of biomolecular signature?' ( 29343408 )
2018
2
The biochemical, nanomechanical and chemometric signatures of brain cancer. ( 28688336 )
2018
3
Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment. ( 29391205 )
2018
4
Inhibition of Translesion DNA Synthesis as a Novel Therapeutic Strategy to Treat Brain Cancer. ( 29259011 )
2018
5
Brain Cancer: Implication to Disease, Therapeutic Strategies and Tumor Targeted Drug Delivery Approaches. ( 29189177 )
2018
6
Curcumin-lipoic acid conjugate as a promising anticancer agent on the surface of golda89iron oxide nanocomposites: A pH-sensitive targeted drug delivery system for brain cancer theranostics. ( 29248558 )
2018
7
Nanotheranostics: Emerging Strategies for Early Diagnosis and Therapy of Brain Cancer. ( 29291164 )
2018
8
Perilesional edema in brain cancer: Independent prognosticator or epiphenomenon of biomolecular signature? ( 29331541 )
2018
9
Biofabrication of morphology improved cadmium sulfide nanoparticles using Shewanella oneidensis bacterial cells and ionic liquid: For toxicity against brain cancer cell lines. ( 29207279 )
2018
10
The Molecular Mechanisms of Plant-Derived Compounds Targeting Brain Cancer. ( 29385679 )
2018
11
A new method using Raman spectroscopy for in vivo targeted brain cancer tissue biopsy. ( 29379121 )
2018
12
Special Issue on Precision Medicine for Brain Cancer in ACS Chemical Neuroscience. ( 29338188 )
2018
13
Biophysical Modeling of InA Vivo Glioma Response After Whole-Brain Radiation Therapy in a Murine Model of Brain Cancer. ( 29398129 )
2017
14
Brain cancer therapy. ( 28104878 )
2017
15
Rethinking Brain Cancer Therapy: Tumor Enzyme Activatable Theranostic Nanoparticles. ( 28929923 )
2017
16
Non-invasive Photodynamic Therapy in Brain Cancer by Use of Tb(3+)-Doped LaF3 Nanoparticles in Combination with Photosensitizer Through X-ray Irradiation: A Proof-of-Concept Study. ( 28110445 )
2017
17
Radiochemical Evaluation and <i>In Vitro</i> Assessment of the Targeting Ability of a Novel <sup>99m</sup>Tc-HYNIC-RGD for U87MG Human Brain Cancer Cells. ( 28681701 )
2017
18
Targeted Drug Delivery via Folate Receptors for the Treatment of Brain Cancer: Can the Promise Deliver? ( 28842300 )
2017
19
Genetically engineered rat gliomas: PDGF-driven tumor initiation and progression in tv-a transgenic rats recreate key features of human brain cancer. ( 28358926 )
2017
20
Combined Proteomic-Molecular Epidemiology Approach to Identify Precision Targets in Brain Cancer. ( 28657708 )
2017
21
Metabolomic signature of brain cancer. ( 28618012 )
2017
22
Risk of severe acute liver injury among patients with brain cancer treated with temozolomide: a nested case-control study using the healthcore integrated research database. ( 28717885 )
2017
23
Role of key genetic mutations on increasing migration of brain cancer cells through confinement. ( 28620782 )
2017
24
Fitness, body composition and vascular health in adolescent and young adult survivors of paediatric brain cancer and cranial radiotherapy. ( 28930627 )
2017
25
Pneumonia diagnosis in childhood and incidence of leukaemia, lymphoma and brain cancer: a Danish nationwide cohort study. ( 29289943 )
2017
26
Using Epigenetic Reprogramming to Treat Pediatric Brain Cancer. ( 28486100 )
2017
27
The roles of microglia/macrophages in tumor progression of brain cancer and metastatic disease. ( 28410147 )
2017
28
Radiomic Phenotyping in Brain Cancer to Unravel Hidden Information in Medical Images. ( 28079714 )
2017
29
Trends in brain cancer mortality among U.S. Gulf War veterans: 21 year follow-up. ( 28780478 )
2017
30
Toxicity of Cisplatin-Loaded Poly Butyl Cyanoacrylate Nanoparticles in a Brain Cancer Cell Line: Anionic Polymerization Results ( 28440967 )
2017
31
Is myelin basic protein a potential biomarker of brain cancer? ( 29028399 )
2017
32
Towards Targeting PI3K-Dependent Regulation of Gene Expression in Brain Cancer. ( 28556811 )
2017
33
Largest brain cancer study offers clues to inherited risk. ( 28722792 )
2017
34
Time-A and oxygen-dependent expression and regulation of NDRG1 in human brain cancer cells. ( 28498432 )
2017
35
HIF-1I+- Targeting Acriflavine Provides Long Term Survival and Radiological Tumor Response in Brain Cancer Therapy. ( 29097800 )
2017
36
A mathematical theory of shape and neuro-fuzzy methodology-based diagnostic analysis: a comparative study on early detection and treatment planning of brain cancer. ( 28321787 )
2017
37
Brain Cancer Stem Cells in Adults and Children: Cell Biology and Therapeutic Implications. ( 28374184 )
2017
38
Corrigendum to "Inferring the 1985-2014 impact of mobile phone use on selected brain cancer subtypes using Bayesian structural time series and synthetic controls" [Environ. Int. (2016), 97, 100-107]. ( 28131518 )
2017
39
Enhancement of apoptotic activities on brain cancer cells via the combination of I^-tocotrienol and jerantinine A. ( 28545672 )
2017
40
The small-molecule kinase inhibitor D11 counteracts 17-AAG-mediated up-regulation of HSP70 in brain cancer cells. ( 28542269 )
2017
41
Detecting and treating brain cancer. ( 28611178 )
2017
42
Utility of neurological smears for intrasurgical brain cancer diagnostics and tumour cell percentage by DESI-MS. ( 28112301 )
2017
43
QuickStats: Brain Cancer Death Rates Among Children and Teens Aged 1-19 Years,* by Sex(a8 ) and Age Group - United States, 2013-2015. ( 28472022 )
2017
44
Nasal HPpSIS administration enhances NGF and tumor suppressor protein, p73 in human brain cancer tissues: preliminary data. ( 28239803 )
2017
45
Robust and fast characterization of OCT-based optical attenuation using a novel frequency-domain algorithm for brain cancer detection. ( 28327613 )
2017
46
British-led research uncovers new details on brain cancer. ( 28421936 )
2017
47
Brain cancer: Temozolomide improves outcomes. ( 28857072 )
2017
48
Increased risk of brain cancer incidence in stroke patients: a clinical case series, population-based and longitudinal follow-up study. ( 29312585 )
2017
49
Characterization of PTEN mutations in brain cancer reveals that pten mono-ubiquitination promotes protein stability and nuclear localization. ( 28263967 )
2017
50
Disparities in Brain Cancer in the United States: A Literature Review of Gliomas. ( 29099032 )
2017

Variations for Brain Cancer

ClinVar genetic disease variations for Brain Cancer:

6 (show top 50) (show all 68)
# Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.6(PTEN): c.1003C> T (p.Arg335Ter) single nucleotide variant Pathogenic/Likely pathogenic rs121909231 GRCh37 Chromosome 10, 89720852: 89720852
2 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
3 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
4 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
5 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
6 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Pathogenic/Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
7 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
8 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
9 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
10 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
11 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
12 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
13 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
14 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
15 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
16 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
17 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
18 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
19 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
20 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic/Likely pathogenic rs113488022 GRCh37 Chromosome 7, 140453136: 140453136
21 BRAF NM_004333.4(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913338 GRCh37 Chromosome 7, 140453154: 140453154
22 ALK NM_004304.4(ALK): c.3824G> A (p.Arg1275Gln) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs113994087 GRCh37 Chromosome 2, 29432664: 29432664
23 ALK NM_004304.4(ALK): c.3383G> C (p.Gly1128Ala) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs113994088 GRCh37 Chromosome 2, 29445450: 29445450
24 ALK NM_004304.4(ALK): c.3575G> C (p.Arg1192Pro) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs113994089 GRCh37 Chromosome 2, 29443642: 29443642
25 PIK3CA NM_006218.3(PIK3CA): c.1624G> A (p.Glu542Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913273 GRCh37 Chromosome 3, 178936082: 178936082
26 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
27 BRAF NM_004333.4(BRAF): c.1780G> A (p.Asp594Asn) single nucleotide variant Pathogenic/Likely pathogenic rs397516896 GRCh37 Chromosome 7, 140453155: 140453155
28 PIK3CA NM_006218.3(PIK3CA): c.1637A> G (p.Gln546Arg) single nucleotide variant Pathogenic/Likely pathogenic rs397517201 GRCh37 Chromosome 3, 178936095: 178936095
29 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913254 GRCh37 Chromosome 1, 115256530: 115256530
30 TP53 NM_000546.5(TP53): c.488A> G (p.Tyr163Cys) single nucleotide variant Pathogenic/Likely pathogenic rs148924904 GRCh37 Chromosome 17, 7578442: 7578442
31 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
32 TP53 NM_000546.5(TP53): c.580C> T (p.Leu194Phe) single nucleotide variant Pathogenic/Likely pathogenic rs587780071 GRCh37 Chromosome 17, 7578269: 7578269
33 TP53 NM_000546.5(TP53): c.659A> G (p.Tyr220Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
34 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
35 TP53 NM_000546.5(TP53): c.422G> A (p.Cys141Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587781288 GRCh38 Chromosome 17, 7675190: 7675190
36 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic/Likely pathogenic rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
37 TP53 NM_000546.5(TP53): c.706T> G (p.Tyr236Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587782289 GRCh37 Chromosome 17, 7577575: 7577575
38 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh38 Chromosome 2, 208248388: 208248388
39 PIK3CA NM_006218.3(PIK3CA): c.353G> A (p.Gly118Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587777790 GRCh38 Chromosome 3, 179199690: 179199690
40 PIK3CA NM_006218.3(PIK3CA): c.3129G> A (p.Met1043Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913283 GRCh38 Chromosome 3, 179234286: 179234286
41 TP53 NM_000546.5(TP53): c.856G> A (p.Glu286Lys) single nucleotide variant Pathogenic/Likely pathogenic rs786201059 GRCh37 Chromosome 17, 7577082: 7577082
42 PTEN NM_000314.6(PTEN): c.517C> T (p.Arg173Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913293 GRCh37 Chromosome 10, 89711899: 89711899